Asthma. Asthma
Conditions
Interventions
Intervention 1: Beclomethasone 250 microgram MDI to 6 puffs /d ( 1500 microgram ) for 3 weeks by spacer. Intervention 2: Fluticasone MDI 250 microgram to 6 puffs/d ( 1500 microgram ) for 3 weeks by
Treatment - Drugs
Beclomethasone 250 microgram MDI to 6 puffs /d ( 1500 microgram ) for 3 weeks by spacer.
Fluticasone MDI 250 microgram to 6 puffs/d ( 1500 microgram ) for 3 weeks by spacer
Sponsors
Endocrine Research Center, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Presence of moderate asthma Exclusion criteria: cigarette smoking, occupational asthma, history of systemic steroid use during the last 6 months, low compliance for 1500 microgram MDI use, consumption of systemic steroid during the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum cortisol levels. Timepoint: 0, 30, and 60 min. after ACTH in ther 1st and last session after (3 weeks). Method of measurement: Serum Cortisol levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: First and 3 weeks 3 after increased MDI dose. Method of measurement: Serum glucose fasting level.;Spirometric values. Timepoint: 3 weeks later. Method of measurement: Spirometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKeivan Gohari Moghadam
Tehran University of Medical Sciences, Faculty of Medicine , Shariati hospital
Outcome results
None listed